💸 The Tape

President Trump announced Wednesday he will nominate Dr. Heidi Overton as the next Commissioner of the Food and Drug Administration, elevating the deputy director of the White House Domestic Policy Council to run the agency that will decide — more than the DEA, more than Congress — what happens to cannabis and psychedelics as medicine.

If confirmed, Overton inherits an FDA holding several files the cannabis industry has been waiting on for years: the CBD regulatory pathway, the hemp THC framework underlying the November recriminalization, medical marijuana product regulation post-Schedule III, and the psychedelic therapy pipeline now moving at unusual speed.

Anyone hoping for a clean read on where she stands should sit down. On psychedelics, the record is remarkably clear. On cannabis, it is contradictory in ways that matter enormously.

Who she is

Overton is from Gallup, New Mexico, graduated summa cum laude from the University of New Mexico, took her MD from the UNM School of Medicine and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health. She is board-certified in public health and general preventive medicine.

She was a White House Fellow from 2019 to 2021, then served as chief policy officer and vice chair of the Center for a Healthy America at the America First Policy Institute, and returned in January 2025 as Deputy Assistant to the President for Domestic Policy. She helped lead the administration's response to the 2026 Central Africa Ebola epidemic and worked on the revised federal food guidance.

She replaces Marty Makary, who resigned in May under White House pressure. Confirmation runs through the Senate HELP Committee, chaired by Sen. Bill Cassidy.

Psychedelics: unambiguously supportive

This is the part with actual evidence behind it.

Overton was reportedly involved in drafting the executive order to accelerate development of and broaden access to psychedelic therapies. BMO Capital Markets wrote to investors that her visible role in the April 2026 executive order prioritizing FDA review of ibogaine and MDMA-based therapies highlights the administration's approach to psychedelics as medicine. Truist Securities made the same point, noting she ran the inter-agency process on the psychedelics/ibogaine EO.

BioSpace's read on analyst reaction was blunt: good for psychedelics and non-opioid pain medicine.

For companies in the psychedelic therapeutics pipeline, that's about as favorable a signal as an FDA nomination can produce. She ran the process that produced the order, she understands the regulatory mechanics, and she comes from a clinical-investigation background that treats these compounds as drugs requiring trials — not as scheduling questions.

That last distinction is the key to everything else.

Cannabis: the conflicting record

Here the picture fractures, and the fracture is instructive.

The Atlantic reported that MAHA-aligned figures accused Overton of slowing down Trump and RFK Jr.'s policy goals, specifically opposing softening rules for marijuana and psychedelics. One person familiar with her work said her instinct was to dig in and resist until the president's friends called him directly and overrode her — citing psychedelic treatments for veterans and marijuana rescheduling as examples.

Inside HHS, the joke was that proposals sent to the White House fell into the "Overton window" of inaction.

So which is it? She drafted the psychedelic EO and she resisted psychedelic access. Both appear to be true, and the reconciliation is the most important thing to understand about her.

Overton is not a drug-policy liberalizer. She is a process person with a clinical-trials worldview. The Rogan-driven psychedelic order came together in weeks after a direct appeal to Trump; Overton's role was running the interagency process that made it executable. Her resistance wasn't to the compounds — it was to moving them through political channels rather than evidentiary ones.

For an FDA commissioner, that is arguably the correct disposition. For an industry hoping the White House will simply declare things safe, it is not what it wanted.

What that means, category by category

CBD. The FDA has now spent seven years declining to create a pathway, having rejected citizen petitions and told Congress that a new framework is needed but must come from legislation. Overton's clinical background suggests she'll want data — dose-response, hepatotoxicity, drug interaction — before opening a dietary supplement route. Notably, though, CMS Administrator Dr. Oz has personally lobbied senators to protect senior CBD access pending Medicare coverage decisions under the CBD Pilot Program, and Trump has publicly pressed to preserve full-spectrum CBD. Overton has worked directly with Oz. CBD is the likeliest area of movement, and it's the one with White House air cover.

Hemp and intoxicating THC. The 0.4mg total-THC per container limit takes effect November 12 unless Congress moves it — the Senate CR pushes it to December 11. The Van Duyne-Landsman Beverage Regulatory Parity Act would route hemp drinks through TTB, HHS and USDA. HHS means FDA, and FDA means Overton. Her preventive-medicine training and the administration's stated concern about products marketed to children point toward supporting the synthetic-cannabinoid ban while being open to a regulated, dosed beverage category. She is unlikely to be the industry's advocate on inhalables.

Medical versus adult-use. This is the cleanest inference available. Someone who thinks in INDs, endpoints and controlled trials will treat medical cannabis as a drug-development question — meaning support for research pathways, and near-zero interest in adult-use commerce, which isn't FDA's remit anyway. Post-Schedule III, FDA's leverage runs through product regulation and approval pathways, and Overton will likely use it to push toward pharmaceutical-grade standards rather than state-market accommodation.

The read

The industry has spent a year hoping for political sponsors. It got a clinical investigator with a PhD in trial design who reportedly slowed the president's own allies when they tried to move faster than the evidence.

For psychedelic therapeutics companies running real trials, that's a strong outcome — she built the process they'll be running through. For pharmaceutical cannabis and API developers, it's neutral-to-positive: FDA pathways favor GMP-grade producers. For hemp operators hoping for federal permissiveness, it's the least accommodating profile available.

Confirmation isn't assured — Sen. Patty Murray already called her a far-right extremist unfit for the job, and Cassidy has criticized administration vaccine moves.

But if she's confirmed, the message is consistent: bring data, not phone calls.

📈 Dog Walkers

$CWBHF ( ▲ 9.27% ) Hits The Road

Charlotte's Web Holdings (TSX: CWEB) (OTCQX: CWBHF) has launched Route CBD, a pop-up truck touring communities along the California-Nevada border from August 11 through September 10 — letting consumers share stories, learn about evolving regulations, and legally purchase full-spectrum hemp CBD products they can no longer buy at home.

The occasion is California's regulatory shutdown. On July 1, 2026, the state enacted SB 378 and AB 8 which, alongside emergency regulations previously issued by Gov. Gavin Newsom, eliminated access to full-spectrum hemp products entirely.

The border staging is the point. This isn't a marketing tour — it's a demonstration that demand didn't disappear, it just crossed a state line. Chief Commercial Officer Mindy Garrison noted that on day one the team met a family who drove three hours across state lines to get products for their daughter, framing the issue as quality of life rather than convenience.

That framing carries unusual weight coming from this company. Charlotte's Web was founded around one family's search for something to help their daughter, Charlotte — the origin story the entire CBD category is named after.

CEO Bill Morachnick drew the distinction that matters most for the policy fight: lawmakers need to know the difference between therapeutic products versus intoxicating, synthetic ones.

That's the strategic play. With the federal hemp ban effective November 12 and the Senate's continuing resolution moving it to December 11 — the industry is splitting into two camps. Charlotte's Web is planting itself firmly on the CBD side, where Dr. Oz and the White House have already signaled sympathy, while synthetic cannabinoids get recriminalized regardless.

The company warns California is a preview of nationwide disruption. It's also a live demonstration of what the ban does to demand: relocates it.

📺 Trade To Black

Curaleaf - Aurora Hostile Bid Heats Up Further | TTB Presented by Flowhub

• Aurora tells shareholders to sit tight. Aurora Cannabis (TSX: ACB) (NASDAQ: ACB) responded to Curaleaf's (TSX: CURA) (OTCQX: CURLF) hostile bid, with Executive Chairman and CEO Miguel Martin urging no action while a special committee reviews the $4.00 per share offer — pushing back on the claim that Aurora refused to engage privately, and accusing Curaleaf of going public specifically to pressure shareholders into a short-term decision.

• A hemp email that isn't as clean as it reads. Shadd Dales and Anthony Varrell break down a note from Brett Worley, CEO of MC Nutraceuticals, claiming hemp's protection is now written into the Senate's base bill text through December 11 — separating what's accurate from what's oversold, including the fact that D8 and HHC aren't naturally derived cannabinoids.

• Flowhub CEO Kyle Sherman drops in to weigh in on all of it — plus the company's new Text-to-Order AI feature.

• Vantage Standard: the TGA extension. COO Deepank Utkhede and Director of Sales Christian Santi explain why an extension of Australian TGA approval matters more than a new one, what cGMP compliance demands continuously, and how TGA, ICH Q7 and a DEA Schedule I license each unlock different high-barrier global markets.